Dirk Haussecker

This seems unusual indeed. $qure

@TraderNorway @BeckyQuick @CNBC @WSJ @statnews @SenRonJohnson @LauraLoomer Do you evidence that they have traded biotech stocks?

$QURE $SRPT There is NO way that @BeckyQuick @CNBC @WSJ @statnews @SenRonJohnson @LauraLoomer havent seen the news that Arnold Ventures have infected FDA and placing their paid scientists there to cut down rare diseases like the patients lifes doesnt matter a second thought. Arnold Ventures paid off @DrMakaryFDA @VPrasadMDMPH while they had top positions and was shorting the same companies while their slaves did their bidding. Absolutely outrageous. Heads needs to fly here and Makary must be the next one to go after Prasad. @realDonaldTrump @WhiteHouse

A full blown scandal. Ideologues funded by and aligned with an ex-Enron trader have been put in charge of the #FDA without any knowledge of how drug innovation works and see cost first instead of progress.

Tomorrow, 3/21, is #Down Syndrome Day. In Germany we remember the Dark Times of #eugenics when they were deported to be disposed of, and even after 1945 long kept out of sight. cc #FDA

@AppleHelix Dunno, as the guy who was the Head Trader of Enron at the time of bankruptcy, I would lay low instead...

Okay, Before today, I knew Arnold Ventures funded Vinay Prasad - but I didn't know the amount. Today I learned that: - Vinay Prasad was funded by ~$4m grants from 2017-23, and continues to be funded by AV - Marty Makary was also funded by AV - $500-$1m in grants - Tracy Beth Hoeg was supported indirectly by Arnold Ventures while working in Vinay Prasad's lab So basically Arnold Ventures was able to place ideologically aligned people at the FDA. TO BE CLEAR, I think @Arnold_Ventures does great things. I agree with its goal of lowering cost of medicines. However, I disagree with its approach. I also think sometimes, they end up funding ideologues - people who wants to "prove" their biases rather than being evidence or fact-driven.

Same goes for biopharma execs who do not speak out against arbitrary, eugenic #FDA any more for fear of becoming a target of the agency. This is why authoritarian regimes persist.

$qure @DrMakaryFDA has been priding himself* that he has signed every single compassionate use request, so why not have the HD community flood them with such requests for AMT-130? *probably just another lie, just as his admin having met every PDUFA

CSL's #hemophilia B gene therapy, licensed from $qure, is slowly becoming a success story, no matter the temporary manufacturing setback: $57M in H2 2025 sales following a slow start in 2023/4, and 51 out of 54 patients prophy free after 5 years! $sgmo

Plot twist...John Arnold, the head trader of #Enron when it filed for bankruptcy who 'made' the fraudulent firm $750M the year before it filed for bankruptcy, has been calling the shots at #FDA: therealarnolds.org/2023/11/16/joh… @DrMakaryFDA #Prasad

👇the moneyed interest behind Prasad, @DrMakaryFDA and their hires at #FDA.

Oh the irony of @DrMakaryFDA calling out rare disease advocacy 'moneyed interest' while pursuing #FDA policies directly aligned with a major financial backer of Prasad and his.

@BiotechTV @SpurTherapeutx An open-label, single-arm phase 3? Good luck with that ( if the US is their target market).

𝐅𝐫𝐨𝐦 𝐋𝐨𝐧𝐝𝐨𝐧: @SpurTherapeutx is in a phase 3 for its gene therapy for Gaucher Disease - using a unique construct that allows them to have a lower dose than other gene therapies. Full video: biotechtv.com/post/spur-ther…

The FDA would rather accept for review drugs which apparently failed placebo controls (p=0.3), but refuse to entertain externally controlled studies which suggest strong efficacy. OK... $srpt $qure

What is wrong with these people? Who would want vulnerable babies not have access to protective neutralizing RSV antibodies? This is evil. #fda

@mike98572986 A key question: did RFK know about it and it therefore was the plan all along? Wouldnt surprise me given the eugenic vision of RFK (e.g. only the weak die from infections).

$qure $clpt $rgnx Think about this for a second. It’s all you need to know. Prasad was paid off to stop rare disease drugs from making it through. The entire world view of Arnold Ventures is rare disease patients aren’t worth saving, the resources would be better off used on healthy individuals. This is extremely sick and disturbing. This should be front page news on every newspaper, television, every single rare disease patient or family member needs to be aware of this. They should be at the White House gates and the FDA building. Makary should step down immediately. This is a monumental scandal and deserves a real investigation. @RepAuchincloss @SenRonJohnson @SenRickScott @SenGillibrand @WhiteHouse @FrankLuntz @SusieWiles @BeckyQuick @HDSA @HDBuzzFeed @Help4HDI @adamfeuerstein @laurencurehd

She should just say the quiet part out loud: one year for a rare disease patient is not worth $500k.

Is it me, or is @DrMakaryFDA suddenly all over the media channels...frantically trying to save his job? foxbusiness.com/video/63911233…

@grok But is CBER not supposed to make regulatory decisions that are not tied to cost considerations? What you say suggests Prasad has been violating US law by doing so.

Funding from Arnold Ventures (AV) continued beyond 2020. Prasad has disclosed ongoing AV research grants (to UCSF) in 2021–2025 publications on drug approvals, costs, surrogates, and evidence quality. AV views rare-disease drugs as part of broader pricing failures: high launch prices (often 7x non-orphan), gene therapies >$1M, CF drugs ~$300k/yr not always justified by R&D. They push evidence-based reforms to cut waste while keeping innovation incentives. Prasad's work (medical reversals, weak endpoints) aligns with AV priorities by stressing rigorous data for high-cost approvals; as ex-CBER head he applied stricter standards to some rare-disease therapies, per public reports. Funders back aligned researchers.

Hey @grok, how significant has funding from Arnold Ventures been to Vinay #Prasad's work as an academician? And would you agree that Prasad's research 'findings' have closely aligned with the policy objectives of AV?

@grok What about funding from AV beyond 2020? What view does AV take on rare disease drug development and cost and what is the impact of Prasad's research findings on these areas?

Vinay Prasad received a $2M, 3-year grant in 2017 from the Laura & John Arnold Foundation (now Arnold Ventures) while at OHSU to identify contradicted treatments/tests, build a public website, and create teaching modules to curb low-value care and spending. He discloses ongoing AV research funding and has called it visionary support enabling his academic work beyond typical NIH constraints. His publications on medical reversal, weak surrogate endpoints, and reducing ineffective practices closely match AV’s stated health priorities: lowering costs via evidence-based policy, cutting low-value/harmful care, and strengthening value in delivery/FDA processes. Funders commonly back aligned researchers.